Neutrophil maturation rate determines the effects of dipeptidyl peptidase 1 inhibition on neutrophil serine protease activity

British Journal of Pharmacology

Volumn , Issue , 2016, Pages 2390-2401

  Gardiner, P ^a   Wikell, C ^a   Clifton, S ^b   Shearer, J ^b   Benjamin, A ^c   Peters, S A ^a,d  

^a ASTRAZENECA R AND D   (Sweden)

^b BioFocus DPI   (United Kingdom)

^c ASTRAZENECA   (United Kingdom)

^d Merck Serono GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO N [1 CYANO 2 (4' CYANOBIPHENYL 4 YL)ETHYL]TETRAHYDRO 2H PYRAN 4 CARBOXAMIDE; CATHEPSIN G; CYSTEINE PROTEINASE INHIBITOR; DIPEPTIDYL PEPTIDASE I; LEUKOCYTE ELASTASE; MYELOBLASTIN; N [1 CYANO 2 (4' CYANOBIPHENYL 4 YL)ETHYL]PIPERIDINE 2 CARBOXAMIDE; NEUTROPHIL SERINE PROTEASE; SERINE PROTEINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BONE MARROW; CELL MATURATION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; MALE; MORNING DOSAGE; NEUTROPHIL; NONHUMAN; PHARMACODYNAMICS; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; RAT; VOLUME OF DISTRIBUTION AT STEADY-STATE;

EID: 84978821810     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13515     Document Type: Article

References (38)

1. Alexander SPH, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015). The concise guide to PHARMACOLOGY 2015/16: Enzymes. Br J Pharmacol 172: 6024–6109.
2. Bekkering S, Torensma R (2013). Another look at the life of a neutrophil. World J Hematol 2: 44–58.
3. BoChiba M, Ishii Y, Sugiyama Y (2009). Prediction of hepatic clearance in human from in vitro data for successful drug development. AAPS J 11: 262–276.
4. Dancey JT, Deubelbeiss KA, Harker LA, Finch CA (1976). Neutrophil kinetics in man. J Clin Invest 58: 705–715.
5. Elborn JS, Perrett J, Forsman-Semb K, Marks-Konczalik J, Gunawardena K, Entwistle N (2012). Efficacy, safety and effect on biomarkers of AZD9668 in cystic fibrosis. Eur Respir J 40: 969–976.
6. Fouret P, du Bois RM, Bernaudin JF, Takahashi H, Ferrans VJ, Crystal RG (1989). Expression of the neutrophil elastase gene during human bone marrow cell differentiation. J Exp Med 169: 833–845.
7. Fox S, Leitch AE, Duffin R, Haslett C, Rossi AG (2010). Neutrophil apoptosis: relevance to the innate immune response and inflammatory disease. J Innate Immun 2: 216–227.
8. Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO (2002). Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol 20: 4713–4721.
9. Fujita J, Nelson NL, Daughton DM, Dobry CA, Spurzem JR, Irino S et al. (1990). Evaluation of elastase and antielastase balance in patients with chronic bronchitis and pulmonary emphysema. Am Rev Respir Dis 142: 57–62.
10. Furber M, Tiden A, Gardiner P, Mete A, Ford R, Millichip I et al. (2014). Cathepsin C inhibitors: Property optimization and identification of a clinical candidate. J Med Chem 57: 2357–2367.
11. Garwicz D, Lindmark A, Hellmark T, Gladh M, Jögi J, Gullberg U (1997). Characterization of the processing and granular targeting of human proteinase 3 after transfection to the rat RBL or the murine 32D leukemic cell lines. J Leukoc Biol 61: 113–123.
12. Guay D, Beaulieu C, David Percival M (2010). Therapeutic utility and medicinal chemistry of cathepsin C inhibitors. Curr Top Med Chem 10: 708–716.
13. Keatings VM, Collins PD, Scott DM, Barnes PJ (1996). Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 153: 530–534.
14. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577–1579.
15. Kolaczkowska E, Kubes P (2013). Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol 13: 159–175.
16. Korkmaz B, Horwitz MS, Jenne DE, Gauthier F (2010). Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases. Pharmacol Rev 62: 726–759.
17. Lalonde R, Kowalski K, Hutmacher M, Ewy W, Nichols D, Milligan P et al. (2007). Model-based drug development. Clin Pharmacol Ther 82: 21–32.
18. Mahmood I (2005). Interspecies scaling of biliary excreted drugs: a comparison of several methods. J Pharm Sci 94: 883–892.
19. McGinnity D, Collington J, Austin R, Riley R (2007). Evaluation of human pharmacokinetics, therapeutic dose and exposure predictions using marketed oral drugs. Curr Drug Metab 8: 463–479.
20. McGrath JC, Lilley E (2015). Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP. Br J Pharmacol 172: 3189–3193.
21. McGuire MJ, Lipsky PE, Thiele DL (1993). Generation of active myeloid and lymphoid granule serine proteases requires processing by the granule thiol protease dipeptidyl peptidase I. J Biol Chem 268: 2458–2467.
22. Méthot N, Guay D, Rubin J, Ethier D, Ortega K, Wong S et al. (2008). In vivo inhibition of serine protease processing requires a high fractional inhibition of cathepsin C. Mol Pharmacol 73: 1857–1865.
23. Méthot N, Rubin J, Guay D, Beaulieu C, Ethier D, Reddy TJ et al. (2007). Inhibition of the activation of multiple serine proteases with a cathepsin C inhibitor requires sustained exposure to prevent pro-enzyme processing. J Biol Chem 282: 20836–20846.
24. Milligan P, Brown M, Marchant B, Martin S, van der Graaf P, Benson N et al. (2013). Model-based drug development: a rational approach to efficiently accelerate drug development. Clin Pharmacol Ther 93: 502–514.
25. Muksinova KN, Murzina LD, Sukhodoev VV (1976). Kinetics of cell populations in the compartment of maturing, non-dividing neutrophils of rat bone marrow. Biull Eksp Biol Med 82: 986–987.
26. Obach RS (1999). Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 27: 1350–1359.
27. Oie S, Tozer TN (1979). Effect of altered plasma protein binding on apparent volume of distribution. J Pharm Sci 68: 1203–1205.
28. Paine SW, Menochet K, Denton R, McGinnity DF, Riley RJ (2011). Prediction of human renal clearance from preclinical species for a diverse set of drugs that exhibit both active secretion and net reabsorption. Drug Metab Dispos 39: 1008–1013.
29. Pillay J, den Braber I, Vrisekoop N, Kwast LM, de Boer RJ, Borghans JA et al. (2010). In vivo labeling with 2H2O reveals a human neutrophil lifespan of 5.4 days. Blood 116: 625–627.
30. Riley RJ, McGinnity DF, Austin RP (2005). A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes. Drug Metab Dispos 33: 1304–1311.
31. Romero-Quintana JG, Frias-Castro LO, Arambula-Meraz E, Aguilar-Medina M, Duenas-Arias JE, Melchor-Soto JD et al. (2013). Identification of novel mutation in cathepsin C gene causing Papillon–Lefevre syndrome in Mexican patients. BMC Med Genet 14: 7. doi:10.1186/1471-2350-14-7.
32. Sinden NJ, Baker MJ, Smith DJ, Kreft J, Dafforn TR, Stockley RA (2014). Alpha-1-antitrypsin variants and the proteinase/anti-proteinase imbalance in chronic obstructive pulmonary disease. Am J Physiol Lung Cell Mol Physiol. doi:10.1152/ajplung.00179.2014.
33. Sorensen OE, Clemmensen SN, Dahl SL, Ostergaard O, Heegaard NH, Glenthoj A et al. (2014). Papillon–Lefevre syndrome patient reveals species-dependent requirements for neutrophil defenses. J Clin Invest 124: 4539–4548.
34. Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ, Alexander SPH et al. (2016). The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucleic Acids Res 44 (Database Issue): D1054–D1068.
35. Stevens T, Ekholm K, Granse M, Lindahl M, Kozma V, Jungar C et al. (2011). AZD9668: pharmacological characterization of a novel oral inhibitor of neutrophil elastase. J Pharmacol Exp Ther 339: 313–320.
36. Stockley R (1994). The role of proteinases in the pathogenesis of chronic bronchitis. Am J Respir Crit Care Med 150: S109.
37. Thong B, Pilling J, Ainscow E, Beri R, Unitt J (2011). Development and validation of a simple cell-based fluorescence assay for dipeptidyl peptidase 1 (DPP1) activity. J Biomol Screen 16: 36–43.
38. Wright HL, Moots RJ, Bucknall RC, Edwards SW (2010). Neutrophil function in inflammation and inflammatory diseases. Rheumatology (Oxford) 49: 1618–1631.